KRW 5490.0
(-0.54%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -22.74 Billion KRW | -191.08% |
2022 | 24.97 Billion KRW | -28.27% |
2021 | 34.81 Billion KRW | 54.65% |
2020 | 22.51 Billion KRW | 418.46% |
2019 | -7.06 Billion KRW | -53.56% |
2018 | -4.6 Billion KRW | -44.97% |
2017 | -3.17 Billion KRW | -94.24% |
2016 | -1.63 Billion KRW | -6.75% |
2015 | -1.53 Billion KRW | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -5.23 Billion KRW | 5.16% |
2024 Q1 | -5.09 Billion KRW | -33.54% |
2023 Q3 | -5.91 Billion KRW | 7.01% |
2023 Q1 | -6.64 Billion KRW | 73.86% |
2023 FY | -22.74 Billion KRW | -191.08% |
2023 Q4 | -3.81 Billion KRW | 35.51% |
2023 Q2 | -6.36 Billion KRW | 4.22% |
2022 Q1 | 44.71 Billion KRW | 288.05% |
2022 FY | 24.97 Billion KRW | -28.27% |
2022 Q4 | -25.42 Billion KRW | -635.8% |
2022 Q3 | -3.45 Billion KRW | -137.81% |
2022 Q2 | 9.13 Billion KRW | -79.56% |
2021 Q1 | 5.49 Billion KRW | 62.88% |
2021 Q2 | -817.56 Million KRW | -114.89% |
2021 Q3 | 18.61 Billion KRW | 2377.34% |
2021 FY | 34.81 Billion KRW | 54.65% |
2021 Q4 | 11.52 Billion KRW | -38.12% |
2020 Q4 | 3.37 Billion KRW | 216.86% |
2020 Q2 | 20.12 Billion KRW | 1080.65% |
2020 Q1 | -2.05 Billion KRW | -9.96% |
2020 FY | 22.51 Billion KRW | 418.46% |
2020 Q3 | 1.06 Billion KRW | -94.72% |
2019 Q3 | -1.76 Billion KRW | 18.89% |
2019 FY | -7.06 Billion KRW | -53.56% |
2019 Q4 | -1.86 Billion KRW | -5.49% |
2019 Q2 | -2.18 Billion KRW | -74.36% |
2019 Q1 | -1.25 Billion KRW | -9.41% |
2018 Q3 | -1.18 Billion KRW | 0.0% |
2018 Q4 | -1.14 Billion KRW | 3.64% |
2018 FY | -4.6 Billion KRW | -44.97% |
2017 FY | -3.17 Billion KRW | -94.24% |
2016 FY | -1.63 Billion KRW | -6.75% |
2015 FY | -1.53 Billion KRW | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 142.82 Billion KRW | 115.923% |
InBody Co.,Ltd | 44.46 Billion KRW | 151.142% |
Curexo Inc. | 1.13 Billion KRW | 2102.918% |
Seegene, Inc. | -30 Billion KRW | 24.215% |
i-SENS, Inc. | 10.92 Billion KRW | 308.08% |
Ray Co., Ltd. | 6.11 Billion KRW | 471.7% |
Gencurix Inc. | -12.37 Billion KRW | -83.759% |
L&C Bio Co., Ltd | 6.66 Billion KRW | 441.12% |